{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=23", "query": { "condition": "Lymphoma (Hodgkin's and Non-Hodgkin's)", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 881, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T06:08:13.738Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004086", "title": "Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "indium In 111 LL2 IgG", "type": "RADIATION" }, { "name": "yttrium Y 90 epratuzumab", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-06-09", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 1, "location_summary": "Belleville, New Jersey", "locations": [ { "city": "Belleville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004086" }, { "nct_id": "NCT02635672", "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "VIP152 (BAY 1251152)", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 30 mg", "type": "DRUG" }, { "name": "Keytruda", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 15 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vincerx Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2016-02-10", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 13, "location_summary": "Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635672" }, { "nct_id": "NCT00201669", "title": "A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2004-10", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00201669" }, { "nct_id": "NCT00427557", "title": "Cellular Therapy With Cord Blood Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Umbilical Cord Blood", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Infusion", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "80 Years", "sex": "ALL", "summary": "Up to 80 Years" }, "enrollment_count": 31, "start_date": "2006-10", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00427557" }, { "nct_id": "NCT00068302", "title": "Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 10, "start_date": "2003-01", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-03-12", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068302" }, { "nct_id": "NCT02576275", "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Indolent Non-Hodgkin's Lymphoma", "Follicular Lymphoma", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SecuraBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-12", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2021-03-17", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 7, "location_summary": "Plainville, Connecticut • Plantation, Florida • Thomasville, Georgia + 4 more", "locations": [ { "city": "Plainville", "state": "Connecticut" }, { "city": "Plantation", "state": "Florida" }, { "city": "Thomasville", "state": "Georgia" }, { "city": "East Setauket", "state": "New York" }, { "city": "Cookeville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576275" }, { "nct_id": "NCT00022581", "title": "Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "thalidomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2001-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022581" }, { "nct_id": "NCT01578967", "title": "Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hodgkin Lymphoma, Adult" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "ABVD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 41, "start_date": "2012-04", "completion_date": "2020-12-11", "has_results": true, "last_update_posted_date": "2021-12-07", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 6, "location_summary": "Duarte, California • Rochester, Minnesota • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578967" }, { "nct_id": "NCT00006473", "title": "Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2000-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006473" }, { "nct_id": "NCT01758042", "title": "Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Kidney Disease", "Acute Myeloid Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)", "Chronic Myelogenous Leukemia (CML)", "Chronic Lymphocytic Leukemia (CLL)", "Non-Hodgkin's Lymphoma (NHL)", "Hodgkin Disease", "Multiple Myeloma", "Myelodysplastic Syndrome (MDS)", "Aplastic Anemia", "AL Amyloidosis", "Diamond Blackfan Anemia", "Myelofibrosis", "Myeloproliferative Disease", "Sickle Cell Anemia", "Autoimmune Diseases", "Thalassemia" ], "interventions": [ { "name": "Haploidentical Bone Marrow/Kidney", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2012-11", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-10-16T06:08:13.738Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01758042" } ] }